Osteoporosis and bone health in HIV

Current HIV/AIDS Reports

Volumn 9, Issue 3, 2012, Pages 218-222

  Powderly, William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antiretroviral therapy; Fractures; HIV; Osteopenia; Osteoporosis; Tenofovir; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCIUM; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; TENOFOVIR; VITAMIN D; ZOLEDRONIC ACID; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE NECROSIS; COMORBIDITY; DISEASE ASSOCIATION; FRACTURE; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OSTEOMALACIA; SECONDARY OSTEOPOROSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRINKING BEHAVIOR; DRUG EFFECT; FEMALE; INFLAMMATION; MALE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; REVIEW; SMOKING; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ALCOHOL DRINKING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; INFLAMMATION; MALE; ORGANOPHOSPHONATES; OSTEOMALACIA; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SMOKING; WEIGHT LOSS;

EID: 84871702084     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0119-7     Document Type: Article

References (49)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. (Pubitemid 28135961)
2. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697-706.
3. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501-15.
4. Kanis JA, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-41. (Pubitemid 24985932)
5. Seeman E, Delmas PD. Bone quality-thematerial and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-61.
6. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501-4.
7. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
8. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375-82. (Pubitemid 38953182)
9. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82. (Pubitemid 29126875)
10. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-90. (Pubitemid 36241317)
11. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIVinfected men irrespective of treatment. J Bone Miner Res. 2004;19:402-9. (Pubitemid 38787395)
12. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIVinfected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-9. (Pubitemid 32423217)
13. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIVon bone in the elderly. Osteoporos Int. 2008;19:913-8.
14. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16:1345-52. (Pubitemid 41534646)
15. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617-23.
16. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395-402.
17. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97:554-62. Further recent evidence of the additional risk associated with HIV, even in populations already at high risk of osteoporosis.
18. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917-23. (Pubitemid 37070277)
19. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23:1-8.
20. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-74. (Pubitemid 44684707)
21. Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92:4522-8. (Pubitemid 350223420)
22. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson- Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIVinfected patients: prevalence and associated factors. AIDS. 2008;22:395-402.
23. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38:893-7. (Pubitemid 44500653)
24. van VonderenMG, Lips P, van AgtmaelMA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ ritonavir. AIDS. 2009;23:1367-76.
25. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60. (Pubitemid 43113030)
26. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-72.
27. McComsey G, Kitch D, Daar E, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-801. Evidence from a randomized controlled trial that tenofovir is associated with increased rates of decreased bone density immediately after initiation of ART.
28. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591-601.
29. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab. 2011;96:2721-31.
30. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-29.
31. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688.
32. Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitaminD deficiency. J Acquir Immune Defic Syndr. 2010;54:496-9.
33. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non- HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-504.
34. Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23:1021-4.
35. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217.
36. Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIVinfected women: results from the Women's Interagency HIV Study. AIDS. 2010;24:2679-86.
37. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285-93.
38. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral gents. AIDS. 2012;26:825-31. First study to date to potentially link tenofovir use to increased risk of fracture.
39. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52:1061-8.
40. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009;25:9-14.
41. Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-82.
42. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72-81. (Pubitemid 351232645)
43. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-46. State-of-the-art guidelines for screening and management of osteoporosis in HIV infection.
44. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453-68. (Pubitemid 34465153)
45. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 2004;5:269-77. (Pubitemid 39545399)
46. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426-31. (Pubitemid 40381552)
47. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473-82. (Pubitemid 350145179)
48. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapytreated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283-8. (Pubitemid 46556399)
49. Huang J, Meixner L, Fernandez S, McCutchan JA. A doubleblinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51-7.